All articles tagged with #prostate cancer
A updated Cochrane review, incorporating data from nearly 800,000 people and longer follow-up, suggests PSA-based prostate cancer screening likely reduces mortality and does not notably increase biopsy or treatment harms, reversing previous Cochrane findings from 2006 and 2013. The absolute benefit is small, and guidelines worldwide remain mixed due to concerns about overdiagnosis and overtreatment.
A new Cochrane review finds PSA blood testing likely reduces death from prostate cancer with moderate certainty, reporting about two fewer disease-specific deaths per 1,000 men screened across six long-term European and North American trials. The benefit is modest and depends on careful implementation, ongoing medical follow-up, and selective biopsies to minimize overdiagnosis and overtreatment; the study does not issue guidelines but supports PSA screening in appropriately selected patients.
A large Cochrane review of six PSA screening trials (nearly 800,000 men) finds PSA testing can reduce prostate cancer deaths, but the absolute benefit is small (about 2 lives saved per 1,000 screened; 500 men need screening to prevent one death). Benefits emerge only with long follow-up, while many men face overdiagnosis and potential harms from treatment, such as incontinence or erectile dysfunction. The authors caution against universal screening and emphasize shared decision making, with targeted approaches for high-risk groups and ongoing development of MRI- and biomarker–based methods whose extra benefit remains uncertain.
A UK analysis of over 400,000 men finds PSA-based prostate cancer screening has low overdiagnosis risk in men in their 50s–60s but rises sharply after 70 due to higher competing mortality; 16% of PSA-detected cancers would not become clinically relevant within 15 years at age 50, rising to 32% at 70 and 58% at 80. Consequently, screening offers little net benefit for men over 70, though MRI-guided biopsy and ongoing trials may reduce harms from overdiagnosis; decisions should be individualized, especially for older men.
Israel's Prime Minister Benjamin Netanyahu says he was treated for prostate cancer and is now healthy, a disclosure he made ahead of attending a Remembrance Day ceremony in Jerusalem.
Israeli Prime Minister Benjamin Netanyahu said a routine checkup found an early-stage malignant prostate tumor that was treated with radiotherapy, leaving no trace of cancer. He did not specify when the treatment occurred and said he delayed releasing his medical report by two months to avoid Iranian propaganda. The report also notes he is in good health; Netanyahu previously had prostate surgery in 2024 and a pacemaker implanted in 2023, with Israel’s elections due in October.
Israeli Prime Minister Benjamin Netanyahu disclosed he was diagnosed with early-stage prostate cancer and underwent treatment, saying he kept the news private for two months to prevent Iran from using it as propaganda amid the war with Iran.
Israeli Prime Minister Benjamin Netanyahu disclosed that a small malignant prostate tumor was found in a routine checkup, he underwent treatment, has fully recovered, and has continued working, noting the cancer did not metastasize as Israel faces a fragile ceasefire with Iran.
Israeli Prime Minister Benjamin Netanyahu said routine medical monitoring after prior prostate surgery detected an early-stage malignant tumor, which was removed with no trace, and that he is in excellent physical condition; he also noted he delayed publishing the health update to avoid propaganda amid tensions with Iran.
Prime Minister Benjamin Netanyahu, 76, has been declared cancer-free after treatment for an early-stage prostate cancer discovered during a routine check; doctors say the cancer was fully removed after a 2024 surgery and subsequent radiation therapy, with no metastasis and complete disappearance of the lesion, and the health report was delayed by two months to avoid Iran using his medical condition for propaganda during the war.
Researchers report metformin increases Lac-Phe, a molecule tied to energy use and appetite, in prostate cancer patients who aren’t exercising, mimicking an exercise signal and potentially supporting metabolic health during treatment; the effect is not linked to tumor control and requires further study.
A small NYU study found microplastics in 90% of prostate cancer tissue samples, with higher concentrations than in healthy tissue, but researchers caution that causation is not established and the sample size is limited; more research is needed while doctors advise risk-reduction steps and regular screening.
A masked T-cell engager called VIR-5500 demonstrated early promise in an ongoing advanced prostate cancer trial, with 82% of high-dose patients seeing PSA reductions and about half showing tumor shrinkage; masking aims to reduce inflammatory toxicity and enable safer, slower activation, though results are preliminary and not yet peer-reviewed.
UK men face rising prostate cancer diagnoses while a National Screening Committee says broad PSA screening isn’t justified due to risks of overdiagnosis and overtreatment, even as awareness grows and access varies by socioeconomic status. The piece follows men like Bulteel, Pennington, Walsh and Hemans, illustrating how PSA testing can detect cancer early but also lead to difficult treatment paths (surgery, radiotherapy, hormone therapy) and significant emotional and relational strain, highlighting disparities in access and the push for targeted screening for at‑risk groups.
Australian researchers show that PSMA PET/CT scans light up aggressive prostate cancers so clearly that many patients with inconclusive MRI can avoid invasive biopsies, potentially halving biopsy rates without missing clinically significant disease; the Primary2 trial (about 660 men) found that those with negative scans did not need biopsies and those with positive scans had targeted biopsies, with two-year follow-up and increasing availability in Australia and Europe.